Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncoethix gets rights to Mitsubishi Tanabe's bromodomain inhibitor for cancer

Executive Summary

Mitsubishi Tanabe Pharma Corp. has granted Oncoethix SA (oncology) exclusive worldwide rights, excluding certain Asian territories, to its Phase I small-molecule bromodomain inhibitor indicated for hematological malignancies. Oncoethix has coded the compound OTX015.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register